All In Biotech

Drug Trial Radar · NCT06817096

Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

Phase 3, Multicenter, Parallel, Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Nitazoxanide 600 Mg Administered Twice Daily, in the Outpatient Treatment of COVID-19 and Influenza

Last checked: Nov 20, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Feb 2025

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Azidus BrasilIndustry
Sponsor type
Industry
Collaborators
Farmoquimica S.A.
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

2\. Participants will: * Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. * Visit the clinic on the 7th day of treatment for a check-up and safety tests. * Keep a diary of their symptoms and other medications used

Conditions

  • Covid 19
  • Influenza

Interventions

  • Nitazoxanide 600Mg Oral Tablet / placebo oral tabletDrug

    1 tablet every 12 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of the Effectiveness of Nitazoxanide in the Outpatient Treatment of COVID-19Time frame: From enrollment to the end of treatment will last up to 60 days
  2. Evaluation of the Effectiveness of Nitazoxanide in the Outpatient Treatment of InfluenzaTime frame: From enrollment to the end of treatment will last up to 60 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.